What drives cancer clinical trial accrual? An empirical analysis of studies leading to FDA authorisation (2015–2020)
Objective To examine factors associated with accrual rate in industry sponsored clinical trials supporting US Food and Drug Administration (FDA) cancer drug approvals from 2015 to 2020.Design, setting and participants Retrospective cross-sectional study included 194 pivotal trials supporting cancer...
Main Authors: | Vinay Prasad, Kristina Jenei, Alyson Haslam, Timothée Olivier, Milos Miljkovíc |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2022-10-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/12/10/e064458.full |
Similar Items
-
Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020
by: Timothée Olivier, et al.
Published: (2023-05-01) -
Additional considerations before using a ctDNA-guided approach for informing adjuvant chemotherapy in colorectal cancer
by: Timothée Olivier, et al.
Published: (2023-09-01) -
Sotorasib in KRASG12C mutated lung cancer: Can we rule out cracking KRAS led to worse overall survival?
by: Timothée Olivier, et al.
Published: (2023-02-01) -
Umbrella review of basket trials testing a drug in tumors with actionable genetic biomarkers
by: Alyson Haslam, et al.
Published: (2023-01-01) -
Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysisResearch in context
by: Adriana M. Ivama-Brummell, et al.
Published: (2023-06-01)